Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

ClinicalTrials.gov ID: NCT02015234

Public ClinicalTrials.gov record NCT02015234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia. Patients recruited into this trial were those who had successfully completed the double-blind study, TNX-CY-F202 (F202) (NCT01903265). Patients were not made aware of the therapy they received during the double-blind study.

Study identification

NCT ID
NCT02015234
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Enrollment
158 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2013
Primary completion
Jul 31, 2015
Completion
Jul 31, 2015
Last update posted
Jul 6, 2017

2013 – 2015

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Denver Denver Colorado 80239
16176 Cortez Boulevard Brooksville Florida 34601
100 West Gore Street Orlando Florida 32806
71 Thomas Johnson Drive Frederick Maryland 21702
370 Faunce Corner Road North Dartmouth Massachusetts 02747
Worcester Worcester Massachusetts 01605
Jackson Jackson Mississippi 39202
Cincinnati Cincinnati Ohio 45219
1275 Olentangy River Road Columbus Ohio 43212
18660 Bagley Road Middleburg Heights Ohio 44130
1001 South Market Street Mechanicsburg Pennsylvania 17055
322 Memorial Drive Greer South Carolina 29650
601 Broadway Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02015234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02015234 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →